Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Atossa Genetics Inc (NASDAQ:ATOS)

Delayed Data
As of Mar 24
 +0.0307 / +2.82%
Today’s Change
Today|||52-Week Range
Health Technology
Medical Specialties

Company Description

Atossa Genetics, Inc. is a clinical-stage pharmaceutical company, which focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. It offers two diagnostic tests: ForeCYTE and ArgusCYTE. The ForeCYTE Breast Health Test provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 65. The ArgusCYTE Breast Health Test provides information to help inform breast cancer treatment options and to help monitor potential recurrence. The company also intends to offer two additional diagnostics tests: FullCYTE and NextCYTE. The FullCYTE Breast Health Test is designed to assess the individual breast ducts for pre-cancerous changes in women previously identified to be at high risk for breast cancer. The NextCYTE Breast Cancer Test is designed to profile breast cancer specimens for prediction of treatment outcomes and distant recurrence in women newly diagnosed with breast cancer. Atossa Genetics was founded by Steven C. Quay in December 2008 and is headquartered in Seattle, WA.

Contact Information

Atossa Genetics, Inc.
2345 Eastlake Avenue
Seattle Washington 98102
P:(206) 588-0256
Investor Relations:



Other institutional3.42%
Mutual fund holders1.93%
Individual stakeholders--

Top Executives

Steven C. QuayChairman, President & Chief Executive Officer
Kyle GuseCFO, Secretary & General Counsel
Janet Rose ReaVP-Regulatory Affairs & Quality